LuciRip

LuciRip uses and dosage

LuciRip (Ripretinib), generic Qinlock, is a prescription medicine used to treat adult patients with advanced or metastatic gastrointestinal stromal tumor (GIST) who have previously received three or more kinase inhibitor therapies, including Imatinib, Sunitinib, and Regorafenib. Ripretinib is a tyrosine kinase inhibitor that targets KIT and PDGFRA mutations, helping to block abnormal signaling pathways responsible for tumor cell growth. By inhibiting these pathways, it helps slow or prevent the progression of tumor cells, particularly in patients whose disease has advanced despite prior standard treatments. LuciRip manufactured by Lucius Pharma Ltd. In Laos. Ripretinib has to take orally once daily with or without food.

LuciRip side effects

The most common side effects of Ripretinib are: Hair loss, Tiredness or weakness, Nausea (feeling like vomiting), Muscle or joint pain, Diarrhea or constipation, Loss of appetite, Hand-foot skin reaction (redness, pain, or peeling on palms or soles).

Originator brand

Qinlock by Deciphera Pharmaceuticals, LLC

Made by

Lucius Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.